Investigating the role of WT1 in a specific type of kidney cancer in children

Who could benefit from this research

What this research studies

This research focuses on Wilms tumor, the most common kidney cancer in children, particularly in high-risk patients who often face poor outcomes. The study aims to understand how mutations in the WT1 and TP53 genes affect tumor behavior and treatment resistance. By exploring the relationship between these mutations, the researchers hope to identify new therapeutic vulnerabilities that could lead to more effective treatments for anaplastic Wilms tumor. The approach involves testing the hypothesis that the loss of function in WT1 and TP53 mutations can be lethal to cancer cells, potentially leading to innovative treatment strategies.

Why it matters

Where this research is happening

• St. Jude Children's Research Hospital
  Memphis, United States Active

Researchers

• Principal investigator: Murphy, Andrew J — St. Jude Children's Research Hospital
• Study coordinator: Murphy, Andrew J

Related research

Other NIH-funded projects on the same topics.

• Fasting-mimicking diet and cancer stem cells in Wilms tumor

  Aiming to see if a fasting-mimicking diet can boost cancer-killing treatment while protecting healthy cells in children with Wilms tumor.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11434150

• Investigating how mutations in a specific gene affect kidney development

  This study is looking at how changes in a specific gene called Wt1 affect the way kidney cells work together during development, which could help us understand kidney formation and problems that might arise, and it's designed for researchers who want to learn more about this process.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-10841677

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Personalized B7-H3 CAR T cells combined with PRAME antigen-specific T cells for relapsed embryonal tumors

  This trial tests a combined personalized B7-H3 CAR T cell and PRAME-specific T cell infusion after lymphodepleting chemotherapy in children and young adults with relapsed or refractory embryonal tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT07172958

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.